Profile data is unavailable for this security.
About the company
BioAtla, Inc. is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for the treatment of solid tumor cancer. The Company’s product candidates include Mecbotamab vedotin (BA3011), Ozuriftabmab vedotin (BA3021), BA3071, and BA3182. Its lead product candidate, BA3011, is a conditionally active biologics (CAB) antibody-drug conjugates (ADC) that targets AXL, which is a protein kinase receptor. The BA3071 is a potential therapeutic for multiple solid tumor types, including soft tissue and bone sarcoma, and non-small cell lung cancer (NSCLC). BA3021 is developing a CAB antibody drug conjugate directed against a receptor tyrosine kinase such as orphan receptor 2 (ROR2). BA3071 is a CAB anti-CTLA-4 antibody that is being developed as a therapeutic for multiple solid tumor indications. BA3182 is designed with an EpCAM binding domain and a CD3 binding domain, both binding domains with CAB activity (Dual-CAB), for the treatment of advanced adenocarcinoma.
- Revenue in USD (TTM)0.00
- Net income in USD-104.56m
- Incorporated2019
- Employees65.00
- LocationBioatla Inc11085 Torreyana RoadSAN DIEGO 92121United StatesUSA
- Phone+1 (858) 558-0708
- Fax+1 (858) 558-0701
- Websitehttps://www.bioatla.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Ikena Oncology Inc | 1.84m | -66.71m | 93.41m | 18.00 | -- | 0.5776 | -- | 50.66 | -1.43 | -1.43 | 0.0393 | 2.96 | 0.0112 | -- | -- | 42,883.72 | -40.52 | -29.72 | -43.17 | -34.62 | -- | -- | -3,617.57 | -294.90 | -- | -- | 0.00 | -- | -41.35 | 56.05 | 0.8711 | -- | 6.30 | -- |
Allovir Inc | 0.00 | -140.34m | 93.49m | 112.00 | -- | 0.7769 | -- | -- | -1.23 | -1.23 | 0.00 | 1.04 | 0.00 | -- | -- | 0.00 | -67.85 | -52.85 | -73.72 | -57.72 | -- | -- | -- | -378,613.90 | -- | -- | 0.00 | -- | -- | -- | -12.87 | -- | -- | -- |
MDxHealth SA | 80.74m | -40.80m | 95.05m | 300.00 | -- | -- | -- | 1.18 | -1.54 | -1.54 | 3.06 | -0.3229 | 0.5906 | 9.39 | 7.49 | 269,136.70 | -29.85 | -51.62 | -43.63 | -64.72 | 62.64 | 50.88 | -50.54 | -117.64 | 0.8252 | -1.74 | 1.18 | -- | 89.43 | 19.84 | 2.14 | -- | 30.13 | -- |
Medicinova Inc | 1.00m | -8.16m | 95.64m | 13.00 | -- | 1.67 | -- | 95.64 | -0.1665 | -0.1665 | 0.0204 | 1.17 | 0.0155 | -- | -- | 76,923.08 | -12.65 | -15.36 | -13.19 | -15.90 | -- | -- | -816.49 | -1,182.54 | -- | -- | 0.00 | -- | -- | -- | 39.08 | -- | 15.87 | -- |
bluebird bio Inc | 54.90m | -311.44m | 95.89m | 375.00 | -- | 1.81 | -- | 1.75 | -2.19 | -2.19 | 0.3574 | 0.2733 | 0.0909 | 3.21 | -- | 146,400.00 | -51.54 | -34.75 | -80.31 | -40.84 | -37.34 | -124.35 | -567.29 | -5,770.41 | 0.5712 | -19.81 | 0.7827 | -- | 720.04 | -11.58 | 8.00 | -- | -30.47 | -- |
Bioatla Inc | 0.00 | -104.56m | 96.67m | 65.00 | -- | 3.08 | -- | -- | -2.18 | -2.18 | 0.00 | 0.6491 | 0.00 | -- | -- | 0.00 | -84.23 | -48.72 | -106.06 | -57.35 | -- | -- | -- | -6,651.71 | -- | -- | 0.00 | -- | -- | -- | -15.95 | -- | -37.01 | -- |
Regulus Therapeutics Inc | 0.00 | -35.39m | 96.89m | 31.00 | -- | 0.9869 | -- | -- | -1.26 | -1.26 | 0.00 | 1.50 | 0.00 | -- | -- | 0.00 | -47.90 | -53.74 | -52.71 | -76.96 | -- | -- | -- | -715.58 | -- | -- | 0.00 | -- | -- | -- | -6.05 | -- | 94.54 | -- |
Oramed Pharmaceuticals, Inc. | 0.00 | 20.86m | 97.85m | 15.00 | 4.80 | 0.5507 | 4.67 | -- | 0.4999 | 0.4999 | 0.00 | 4.36 | 0.00 | -- | -- | 0.00 | 12.19 | -- | 12.29 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -50.43 | -- | 115.11 | -- | -- | -- |
Clearside Biomedical Inc | 7.52m | -33.46m | 97.92m | 30.00 | -- | -- | -- | 13.01 | -0.497 | -0.497 | 0.1119 | -0.3785 | 0.2058 | -- | 59.01 | 250,800.00 | -91.51 | -63.57 | -107.97 | -81.77 | 95.06 | -- | -444.66 | -231.80 | -- | -- | -- | -- | 519.89 | 207.34 | 1.40 | -- | 82.41 | -- |
Tiziana Life Sciences Ltd - ADR | 0.00 | -17.69m | 97.92m | 9.00 | -- | 17.69 | -- | -- | -0.1726 | -0.1726 | 0.00 | 0.0537 | 0.00 | -- | -- | 0.00 | -91.52 | -58.16 | -138.98 | -75.36 | -- | -- | -- | -- | -- | -- | 0.0427 | -- | -- | -- | -14.90 | -- | -- | -- |
Anixa Biosciences Inc | 0.00 | -12.36m | 98.47m | 4.00 | -- | 4.52 | -- | -- | -0.3906 | -0.3906 | 0.00 | 0.6772 | 0.00 | -- | -- | 0.00 | -50.54 | -59.69 | -52.50 | -62.61 | -- | -- | -- | -6,040.10 | -- | -- | 0.00 | -- | -- | -28.36 | 27.83 | -- | -- | -- |
Beyondspring Inc | 1.88m | -15.57m | 99.54m | 35.00 | -- | -- | -- | 53.06 | -0.3987 | -0.3987 | 0.0481 | -0.749 | 0.0698 | -- | -- | 52,111.11 | -59.75 | -75.50 | -102.15 | -96.48 | -- | -- | -856.29 | -4,977.12 | -- | -- | -- | -- | 29.61 | -- | 36.82 | -- | -13.54 | -- |
Agenus Inc | 159.63m | -223.67m | 100.31m | 389.00 | -- | -- | -- | 0.6284 | -11.27 | -11.27 | 8.03 | -11.42 | 0.4723 | -- | 154.98 | 410,357.30 | -68.45 | -55.02 | -281.52 | -115.31 | 99.51 | -- | -144.94 | -102.92 | -- | -0.9185 | -- | -- | 59.47 | 33.56 | -11.66 | -- | 22.58 | -- |
Assembly Biosciences Inc | 21.48m | -45.61m | 101.53m | 65.00 | -- | 2.93 | -- | 4.73 | -9.32 | -9.32 | 4.28 | 5.47 | 0.2362 | -- | 125.62 | 330,476.90 | -50.15 | -39.69 | -69.22 | -44.03 | -- | -- | -212.33 | -409.24 | -- | -- | 0.00 | -- | -- | -13.51 | 34.23 | -- | -5.59 | -- |
Holder | Shares | % Held |
---|---|---|
Soleus Capital Management LP (Investment Management)as of 12 Apr 2024 | 3.89m | 8.09% |
BlackRock Fund Advisorsas of 31 Mar 2024 | 2.53m | 5.27% |
Millennium Management LLCas of 05 Aug 2024 | 2.41m | 5.02% |
The Vanguard Group, Inc.as of 31 Mar 2024 | 2.06m | 4.29% |
Morgan Stanley & Co. LLCas of 31 Mar 2024 | 1.90m | 3.94% |
Tang Capital Management LLCas of 31 Mar 2024 | 1.47m | 3.06% |
Cormorant Asset Management LPas of 31 Mar 2024 | 1.17m | 2.43% |
SSgA Funds Management, Inc.as of 31 Mar 2024 | 791.28k | 1.65% |
DWS Investment Management Americas, Inc.as of 31 Mar 2024 | 692.74k | 1.44% |
Renaissance Technologies LLCas of 30 Jun 2024 | 625.50k | 1.30% |